PeptidePedia The community reference

Contributions of TimelineTiernan

User contributions·22 logged edits·page 1 of 1

Contributions by TimelineTiernan, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 633 edits includes activity predating the current log.

  1. 13:07, 22 Jun 2026 (diff | hist) GLP-1 receptor agonist 11,264 ±0 rm the equipotency claim — the cited paper does not make it
  2. 13:50, 31 May 2026 (diff | hist) Talk:Timeline of incretin therapeutics 748 +73 /* Approval dates are jurisdictional */ reply
  3. 06:31, 27 May 2026 (diff | hist) Retatrutide 7,421 ±0 give the strength per pen as well as per millilitre
  4. 11:54, 20 May 2026 (diff | hist) Reconstitution of lyophilised peptides 5,761 ±0 clarify that the figure is per dose, not per vial
  5. 12:04, 22 Apr 2026 (diff | hist) Semaglutide 10,355 ±0 m give the strength per pen as well as per millilitre
  6. 14:40, 12 Apr 2026 (diff | hist) Orforglipron 5,647 ±0 m add the discontinued indication with its date
  7. 14:45, 10 Mar 2026 (diff | hist) GLP-1 receptor agonist 11,264 ±0 sentence case in headings per PP:MOS
  8. 09:45, 11 Feb 2026 (diff | hist) Talk:Timeline of incretin therapeutics 400 +154 /* The 1986 hinge */ new section
  9. 11:33, 4 Feb 2026 (diff | hist) Liraglutide 5,967 ±0 state which salt form the mass in the infobox refers to
  10. 12:13, 30 Dec 2025 (diff | hist) Sterility testing 4,776 ±0 state the column chemistry and the gradient the figure was obtained on
  11. 21:05, 26 Dec 2025 (diff | hist) Tirzepatide 8,037 ±0 state the substitution in one-letter code as well, per PP:MOS
  12. 12:50, 20 Nov 2025 (diff | hist) Third-party testing 7,489 ±0 m ce, tighten prose
  13. 13:00, 5 Jun 2025 (diff | hist) Counterfeit peptide 4,235 ±0 add category for certificates of analysis
  14. 12:32, 30 May 2025 (diff | hist) Certificate of analysis 8,593 ±0 m state the date range the submitted set covers
  15. 20:24, 3 May 2025 (diff | hist) Arcuate nucleus 4,321 ±0 expand §Neuronal populations
  16. 17:50, 14 Apr 2025 (diff | hist) Orforglipron 4,465 +300 split §Pharmacology into receptor binding and downstream signalling
  17. 12:14, 25 Mar 2025 (diff | hist) SUSTAIN trial programme 4,187 ±0 expand §Relationship to the obesity programme
  18. 07:04, 11 Feb 2025 (diff | hist) Cost per milligram 2,123 +206 add the manufacturer assistance programme with its eligibility criterion
  19. 06:26, 21 Jan 2025 (diff | hist) Tirzepatide 5,389 ±0 add CAS number, sourced
  20. 04:57, 6 Dec 2024 (diff | hist) Exenatide 3,389 +454 m correct the dose ladder — the maintenance dose is not the maximum dose
  21. 05:21, 23 Oct 2024 (diff | hist) Oral semaglutide 2,537 ±0 British spelling per PP:MOS
  22. 09:00, 2 Oct 2024 (diff | hist) Amylin receptor agonist 1,601 +1,601 N start article on the compound